⌘+K

Pulse Explore Communities Researchers Journals

Home Communities Explore

July 3, 2026BMJOpen Access

Peptides: FDA appointed advisory committee criticised for conflicts of interest

View Full Paper

Ask AI

Bookmark

Share

Key Points

The aim is to address concerns regarding conflicts of interest within the FDA advisory committee evaluating peptide compounding safety.
Review of bulk drug substances used in compounding
Analysis of safety risks associated with selected substances
Assessment of advisory committee members' financial disclosures
The advisory committee identified significant safety risks with certain bulk drug substances.
Concerns were raised about conflicts of interest among committee members affecting decision-making.

Implication

Advisory committee reviews safety risks of certain drug substances, highlighting potential conflicts of interest.

Abstract

No abstract yet. The journal hasn't published one we can show.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Leslie Liang (2026) studied this question.

synapsesocial.com/papers/6a4b453d997070ff83b5b06c https://doi.org/10.1136/bmj-2026-100181

View Full Paper

Ask AI

Bookmark

Share

Keep reading

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1Peptides, FDA’s Pharmacy Compounding Advisory Committee, and the Future of FDA Drug ApprovalOriginal Research · 2026
2Under FDA, Unapproved Peptides Likely to Become More Widely AvailableOriginal Research · 2026 · 1 citations
3Review of Clinical Pharmacology Information for Peptides Found in US FDA Drug LabelingReview · 2025 · 3 citations
4Anesthetic and Analgesic Drug Products Advisory Committee Activity and Decisions in the Opioid-crisis Erareview · 2020 · 9 citations
5The “microdosing” dilemma: Balancing patient anecdotes with clinical safety amid GLP-1 compounding restrictionsOriginal Research · 2026

Exploring FDA-Approved Frontiers: Insights into Natural and Engineered Peptide Analogues in the GLP-1, GIP, GHRH, CCK, ACTH, and α-MSH Realms2024
The US Food and Drug Administration Cardiorenal Advisory Panel and the Drug Approval Process2005
A novel, widespread impurity in mass-compounded tirzepatide/b12 products: patient safety implications2026
A proper 24/7 emergency care service is needed in the NHSBMJ · 2013
Are hard collars necessary for older people with odontoid neck fractures?BMJ · 2023